Successful treatment of refractory prurigo nodularis with abrocitinib

Key Clinical MessagePrurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK –STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a conclusion that abrocitinib as an inhibitor of Jak is a promising choice for the treatment of prurigo nodularis.

Source: Clinical Case Reports - March 7, 2024 Category: General Medicine Authors: Fang Sun, Zhenzhen Wu Tags: CASE REPORT Source Type: research